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ARTICLE
Epidemiology
CYP3A7*1C allele: linking premenopausal oestrone and
progesterone levels with risk of hormone receptor-positive
breast cancers
Nichola Johnson et al.
BACKGROUND: Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast
cancer. The aim of this analysis was to identify genetic variants that are associated with urinary sex-hormone levels and breast
cancer risk.
METHODS: We carried out a genome-wide association study of urinary oestrone-3-glucuronide and pregnanediol-3-glucuronide
levels in 560 premenopausal women, with additional analysis of progesterone levels in 298 premenopausal women. To test for the
association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer
Association Consortium. All women were of European ancestry.
RESULTS: For pregnanediol-3-glucuronide, there were no genome-wide significant associations; for oestrone-3-glucuronide, we
identified a single peak mapping to the CYP3A locus, annotated by rs45446698. The minor rs45446698-C allele was associated with
lower oestrone-3-glucuronide (−49.2%, 95% CI −56.1% to −41.1%, P= 3.1 × 10–18); in follow-up analyses, rs45446698-C was also
associated with lower progesterone (−26.7%, 95% CI −39.4% to −11.6%, P= 0.001) and reduced risk of oestrogen and
progesterone receptor-positive breast cancer (OR= 0.86, 95% CI 0.82–0.91, P= 6.9 × 10–8).
CONCLUSIONS: The CYP3A7*1C allele is associated with reduced risk of hormone receptor-positive breast cancer possibly mediated
via an effect on the metabolism of endogenous sex hormones in premenopausal women.
British Journal of Cancer (2021) 124:842–854; https://doi.org/10.1038/s41416-020-01185-w
BACKGROUND
Epidemiological studies provide strong evidence for a role of
endogenous hormones in the aetiology of breast cancer.1,2 Pooled
analyses of data from prospective studies estimated that a
doubling of circulating oestradiol or oestrone was associated with
a 30–50% increase in breast cancer risk in postmenopausal
women and a 20–30% increase in breast cancer risk in
premenopausal women; there was no evidence that premeno-
pausal progesterone levels were associated with breast cancer
risk.2,3 We have previously screened 642 SNPs tagging 42 genes
involved in sex steroid synthesis or metabolism, and tested for the
association with premenopausal urinary oestrone glucuronide and
pregnanediol-3-glucuronide levels, measured in urine samples
collected at pre-specified days of the woman’s menstrual cycle.4
Oestrone-3-glucuronide and pregnanediol-3-glucuronide are urin-
ary metabolites of oestrogen and progesterone, respectively,5,6
that are used in the context of reproductive medicine to monitor
ovarian activity.7 None of the variants that we tested was
associated with urinary pregnanediol-3-glucuronide, but a rare
haplotype, defined by two SNPs spanning the cytochrome P450
family 3 subfamily A (CYP3A) gene cluster, was associated with a
highly significant 32% difference in urinary oestrone-3-
glucuronide.4 Fine-scale mapping analyses identified the SNP
rs45446698 as a putative causal variant at this locus; rs45446698 is
one of seven highly correlated SNPs that cluster within the CYP3A7
promoter and comprise the CYP3A7*1C allele.8 A genome-wide
association study (GWAS) of postmenopausal plasma oestradiol
levels found no association at this locus.9 A subsequent GWAS of
pre- and postmenopausal hormone levels similarly found no
association with plasma oestradiol at this locus; they did however
find associations at this locus with DHEAS and progesterone.10
The CYP3A genes (CYP3A5, CYP3A7 and CYP3A4) encode
enzymes that metabolise a diverse range of substrates;11 in
addition to a role in the oxidative metabolism of hormones, CYP3A
enzymes metabolise ~50% of all clinically used drugs, including
many of the agents used in treating cancer.12 CYP3A4, the major
isoform in adults, is predominantly expressed in the liver, where it
is the most abundant P450, accounting for 30% of total CYP450
protein. CYP3A7, the major isoform in the foetus, is generally
silenced shortly after birth.13 In CYP3A7*1C carriers, a region within
www.nature.com/bjc
Received: 27 April 2020 Revised: 21 October 2020 Accepted: 5 November 2020
Published online: 26 January 2021
Correspondence: Nichola Johnson (nichola.johnson@icr.ac.uk)
Extended author information available on the last page of the article
These authors contributed equally: Nichola Johnson, Sarah Maguire, Anna Morra, Pooja Middha Kapoor
These authors jointly supervised this work: Jenny Chang-Claude, Marjanka K. Schmidt, Nick Orr, Olivia Fletcher
Members of the NBCS Collaborators, AOCS Group, ABCTB Investigators and kConFab Investigators are listed above Acknowledgements.
A full list of authors and their affiliations appear at the end of the paper
© The Author(s) 2021 Published by Springer Nature on behalf of Cancer Research UK
the foetal CYP3A7 promoter has been replaced with the equivalent
region from the adult CYP3A4 gene;14 this results in adult
expression of CYP3A7 in CYP3A7*1C carriers and may influence
metabolism of endogenous hormones, exogenous hormones used
in menopausal hormone treatment and clinically prescribed drugs,
including agents used in treating cancer, in these individuals.12,15
In order to identify additional variants that are associated with
premenopausal urinary hormone levels and to further characterise
the associations at the CYP3A locus, we carried out a GWAS of
urinary oestrone-3-glucuronide and pregnanediol-3-glucuronide
levels, using mid-luteal-phase urine samples from women of
European ancestry and followed up by testing for an association
with breast cancer risk in cases and controls from the Breast
Cancer Association Consortium (BCAC). To determine whether the
CYP3A7*1C allele influences metabolism of exogenous hormones,
we evaluated gene-environment interactions with menopausal
hormone treatment for breast cancer risk, and to investigate
whether adult expression of CYP3A7 impacts on agents used in




Generations Study. Full details of the Generations Study have
been published previously.16 Briefly, the Generations Study is a
cohort study of more than 110,000 women from the UK general
population, who were recruited beginning in 2003 and from
whom detailed questionnaires and blood samples have been
collected to investigate risk factors for breast cancer.
British Breast Cancer Study. Full details of the British Breast
Cancer Study have been published previously.17 Briefly, the British
Breast Cancer Study is a national case–control study of breast
cancer, in which cases of breast cancer were ascertained through
the cancer registries of England and Scotland and through the
National Cancer Research Network. Cases were asked to invite a
healthy female first-degree relative with no history of cancer and a
female friend or non-blood relative to participate in the study.
Mammography Oestrogens and Growth Factors study. Full details
of the Mammography Oestrogens and Growth Factors study have
been published previously.18 Briefly, this is an observational study
nested within a trial of annual mammography screening in young
women that was conducted in Britain.19 Approximately 54,000
women aged 39–41 years were randomly assigned to the
intervention arm from 1991 to 1997 and offered annual
mammograms until age 48 years. From 2000 to 2003, women in
the intervention arm who were still participating in this trial were
invited to participate in the Mammography Oestrogens and
Growth Factors study; they were asked to provide a blood sample
and complete a questionnaire detailing demographic, lifestyle and
reproductive factors. More than 8000 women were enrolled in
the study.
GWAS subjects were drawn from the Generations Study (N=
184), the British Breast Cancer Study (N= 284) and the Mammo-
graphy Oestrogens and Growth Factors study (N= 109). To be
eligible for the GWAS analysis of oestrone-3-glucuronide and
pregnanediol-3-glucuronide levels, women had to be having
regular menstrual cycles (i.e., their usual cycle length had to be
between 21 and 35 days) and not using menopausal hormone
therapy or oral contraceptives. All of the women included in this
analysis reported being of European ancestry, and none had been
diagnosed with breast cancer at the time of study recruitment.
Measurement of hormone levels
The protocol for collecting timed urine samples has been
published previously.18 Briefly, a woman’s predicted date of
ovulation was estimated from the date of the first day of her last
menstrual period and her usual cycle length; ovulation was
predicted to occur 14 days before the date of her next menstrual
period. On this basis, women were asked to provide a series of
early morning urine samples on pre-specified days of their cycle.
For this analysis, the mid-luteal-phase sample, taken at 7 days after
the predicted day of ovulation, was used. To confirm that ovulation
had occurred, consistent with the predicted date of ovulation,
pregnanediol-3-glucuronide was measured; to take account of the
differences in volume in early morning urine samples from
different women, we measured creatinine, a waste product of
normal muscle and protein metabolism that is released at a
constant rate by the body. Samples in which pregnanediol-3-
glucuronide, adjusted for creatinine levels, was >0.3 µmol/mol,
were taken forward for measurement of creatinine-adjusted
oestrone-3-glucuronide. Pregnanediol-3-glucuronide and
oestrone-3-glucuronide were analysed by commercial competitive
ELISA Kits (Arbor Assays, Ann Arbor, USA) according to the
manufacturer’s instructions. For pregnanediol-3-glucuronide, the
lower limit of detection was determined as 0.64 nmol/l; intra- and
inter-assay coefficients of variation were 3.7% and 5.2%, respec-
tively. For oestrone-3-glucuronide, the lower limit of detection was
determined as 19.6 pmol/l; intra- and inter-assay coefficients of
variation were 3.5% and 5.9%, respectively. Creatinine was
determined using the creatininase/creatinase-specific enzymatic
method20 using a commercial kit (Alpha Laboratories Ltd. Eastleigh,
UK) adapted for use on a Cobas Fara centrifugal analyser (Roche
Diagnostics Ltd, Welwyn Garden City, UK). For within-run precision,
the coefficient of variation was <3%, while for intra-batch precision,
the coefficient of variation was <5%.
For 303 premenopausal women participating in the Generations
Study (184 as above and an additional 119 for whom timed urine
samples were accrued more recently), urinary progesterone levels
were also measured using an “in house” ELISA. In all, 96-well plates
(Greiner Bio-One GmbH, Frickenhausen, Germany) were coated
with 100 µl of 5 µg/ml GAM (Arbor Assays, Ann Arbor, USA) in
ELISA coating buffer (100 mM Na Bicarbonate, pH 9.6) covered and
incubated in a fridge at 4 °C overnight. Before use, the plates were
washed three times with wash buffer 0.05 M Tris/HCl and 0.05%
Tween 20, pH 7.4 (Tween® 20, Sigma-Aldrich, Inc., St. Louis, MO,
USA). Standards, samples and controls (20 µl per well) were added
to each well, followed by 80 µl of progesterone 3-HRP conjugate
(Astra Biotech GmbH, Berlin, Germany) at 1:10,000 in assay buffer
(PBS pH 7.4 containing 0.1% BSA and 250 ng/ml Cortisol), followed
by 50 μl of monoclonal progesterone Ab (Astra Biotech GmbH,
Berlin, Germany) 1:50,000 in assay buffer. Plates were incubated at
room temperature for 2 h on a microtitre plate shaker (IKA®,
Schuttler MTS4, IKA Labortechnik, Staufen, Germany), then
washed five times with assay wash buffer and 120 µl of substrate
solution (3,3,5,5-tetramethylbenzidine, Millipore Corporation,
Temecula, CA, USA) was added to each well. Plates were incubated
at room temperature without shaking in the dark. After 20 min,
the reaction was stopped by adding 80 µl of 2 N H2SO4 solution
(Sigma-Aldrich Company Ltd., Dorset, UK). Finally, the plates were
read on a plate reader at 450 nm. Standard curves were prepared
with a total of eight different concentrations (16, 8, 4, 2, 1, 0.5, 0.25
and 0 ng/ml). Samples, standards and controls were included in
duplicate. Inter- and intra-assay coefficients of variation were
calculated from two controls of low and high progesterone in
duplicate in each of eight assays. The inter-assay coefficients of
variation for low and high pools, respectively, were 11.4 and 9.1%;
the intra-assay coefficients of variation were 8.9 and 5.6%. The
lower limit of detection was calculated at 0.1 ng/ml. Cross-reaction
with other steroids was oestrone: 0.17%, oestradiol: 0.28%,
oestriol: 0.18%, dehydroepiandrosterone: 0.02%, testosterone:
0.36%, dihydrotestosterone: 0.15%, 17α-hydroxyprogesterone:
2.9%, androstenedione: 0.14%, 11-deoxycortisol: 0.46%, corticos-
terone: 0.18%, cortisone: 0.04% and cortisol: 0.04%.
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GWAS genotyping and quality control
DNA from 577 women was genotyped using Illumina Infinium
OncoArray 500 K BeadChips. We excluded samples for which
<95% of SNPs were successfully genotyped. Identity-by-descent
analysis was used to identify closely related individuals enabling
exclusion of first-degree relatives. We applied SmartPCA21 to our
data and used phase II HapMap samples to identify individuals
with non-Caucasian ancestry. The first two principal components
for each individual were plotted, and k-means clustering was used
to identify samples separated from the main Caucasian cluster.
SNPs with call rates <95% were excluded, as were SNPs with minor
allele frequency (MAF) < 2% and those whose genotype frequen-
cies deviated from Hardy–Weinberg proportions at P < 1 × 10–05.
Following QC, 487,659 SNPs were successfully genotyped in
560 samples (Generations Study: N= 179, British Breast Cancer
Study: N= 278 and Mammography Oestrogens and Growth
Factors study: N= 103). Genome-wide imputation was performed
using 1KGP Phase 3 reference data. Haplotypes were pre-phased
using SHAPEIT2.22 Imputation was performed using IMPUTE2.23
Imputed SNPs with INFO scores <0.8 and MAFs <2% were
excluded from subsequent analyses. After QC, a set of
7,792,694 successfully imputed SNPs were available for association
analysis.
Genotyping rs45446698 and sequencing of the CYP3A7*1C allele
For the 119 Generations Study women who were not included in
the GWAS but for whom progesterone was subsequently
measured, rs45446698 was genotyped by TaqMan (Thermo Fisher
Scientific Ltd, UK). The call rate was 100% with 100% concordance
between 12 duplicates. To confirm that rs45446698 tags the
CYP3A7*1C allele, we sequenced this region in 31 women selected
on the basis of their rs45446698 genotype (9 common homo-
zygotes and 22 carriers). A 370-bp DNA region (chr7: 99 332 745-
99 333 114; GRCh37/hg19) was amplified using Phusion High-
Fidelity DNA Polymerase (New England Biolabs, UK) and primers
CCATAGAGACAAGAGGAGA (forward) and CTGAGTCTTTTTTTCAG-
CAGC (reverse). The PCR product was purified using QIAquick Gel
Extraction Kit (Qiagen) and Sanger sequenced using a commer-
cially available service (Eurofins Genomics, Germany).
Statistical analysis of GWAS data
Tests of association between SNP genotypes and log-transformed
creatinine-adjusted oestrone-3-glucuronide and pregnanediol-3-
glucuronide adjusted for study were performed using linear
regression in SNPTEST v2.5.24 Test statistic inflation was assessed
visually using a QQ Plot (Supplementary Fig. S1) and formally by
calculating the inflation factor, λ. There was no evidence of
systematic test statistic inflation (λ= 1.01 for both oestrone-3-
glucuronide and pregnanediol-3-glucuronide). For the single
significant association (rs45446698), we used multivariate linear
regression to adjust for potential confounders: age at menarche
(<12, 12, 13, 14 and >14 years), age at collection of urine samples
(<35, 35–40 and ≥40 years), body mass index (BMI: < 18.5, 18.5–
<20.0, 20.0–<25.0, 25.0–<30.0 and ≥ 30.0 kg/m2) and parity (0, 1, 2
and ≥3 live births).
Follow-up genotyping of rs45446698
Genotype data for rs45446698 were generated as part of iCOGS25
and OncoArray.26 Full details of SNP selection, array design,
genotyping and post-genotyping QC have been published.25,26
Participants genotyped in both collaborations were excluded from
the iCOGS data sets with the exception of the GxE interaction
analysis of menopausal hormone treatment, for which five studies
(CPS-II, PBCS, UKBGS, MCCS and pKARMA) were excluded from
OncoArray, rather than iCOGS, in order to maximise the number of
studies with sufficient cases and controls for analysis. We excluded
cases with breast tumours of unknown invasiveness, or in situ
disease, and those for whom age at diagnosis was not known.
After QC exclusions,26 the call rate for rs45446698 in OncoArray
data was 99.66% and there was no evidence of deviation from
Hardy–Weinberg equilibrium in controls (Supplementary Table S1).
In iCOGS data, rs45446698 was imputed using 1KGP Phase 3
reference data (info score= 0.94); we used gene dosages (≤0.2=
0, >0.8 and ≤1.2= 1, >1.8= 2) to call genotypes for 99.22% of
samples.
Statistical analysis of rs45446698 and breast cancer risk
Due to the low MAF of rs45446698 (3.7%, 0.03% and 0.4% in
individuals of European, Asian and African ancestry, respectively),
we restricted our analyses to individuals of European ancestry and
excluded studies with <50 cases or controls; there were 35 (iCOGS)
and 56 (OncoArray) studies for the current case–control analysis
(Supplementary Tables S1 and S2).
We combined heterozygote and rare homozygote genotypes
and estimated carrier ORs using logistic regression, adjusted for 15
principal components25,26 and study. Stratum-specific carrier ORs
were estimated for a set of pre-specified prognostic variables
(oestrogen receptor (ER), progesterone receptor (PR), HER2, grade
and stage). We excluded studies with <50 cases or controls in any
individual stratum from stratified analyses. Interactions were
assessed based on case-only models (ER, PR, Her2, stage and
grade). In the subset of studies for which covariate data were
available, we used multivariable logistic regression to adjust for
reference age (defined as age at diagnosis for cases and age at
interview for controls), age at menarche, BMI and parity (as above).
Finally, we stratified our analyses on menopausal status at
reference age. When menopausal status was missing, the
reference age was used as a surrogate (<54 premenopausal and
≥54 postmenopausal). To select the reference age that most
accurately captured menopausal status in this group of studies, we
generated AUC curves based on women who had reported natural
menopause with different reference age cut-offs (50–56 years); on
this basis, a reference age of 54 was selected. P values were
estimated using likelihood ratio tests with one degree of freedom.
All P values reported, for all analyses, are two-sided. Statistical
analyses were performed using STATA version 11.0 (StataCorp,
College Station, TX, USA).
Statistical analysis of gene-environment interaction (GxE) with
menopausal hormone treatment
Postmenopausal women from 13 (iCOGS) and 27 (OncoArray)
studies provided the data on menopausal hormone treatment.
Menopausal status and postmenopausal hormone use were
derived as of the reference date (defined as date of diagnosis for
cases and interview for controls); women with unknown age at
reference date were excluded from this analysis. All analyses
were conducted only in postmenopausal women. Carrier ORs for
breast cancer risk were estimated using logistic regression
stratified by current use of menopausal hormone treatment,
oestrogen–progesterone therapy and oestrogen-only therapy,
respectively. Analyses were adjusted for study, ten principal
components, reference age, age at menarche, parity, BMI, former
use of menopausal hormone treatment and use of any menopau-
sal hormone treatment preparation other than the one of interest
in analyses of current use of menopausal hormone treatment by
type. To account for potential heterogeneity of the main effects of
menopausal hormone treatment/oestrogen–progesterone ther-
apy/oestrogen-only therapy by study design, we included an
interaction term between the risk factor of interest and an
indicator variable for study design (prospective cohorts/popula-
tion-based case–control studies, non-population-based studies).
Interactions between rs45446698 and current use of menopausal
hormone treatment, oestrogen–progesterone therapy and
oestrogen-only therapy were assessed using likelihood ratio tests,
based on logistic regression models with and without interaction
between rs45446698 and current use of menopausal hormone
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treatment, oestrogen–progesterone therapy and oestrogen-only
therapy, respectively. Statistical analyses were performed using
SAS 9.4 and R (version 3.4.4).
Statistical analysis of breast cancer-specific survival in cases
In total, 38 (iCOGS) and 63 (OncoArray) studies provided follow-up
data for analysis of breast cancer-specific survival. Analysis of
outcome was restricted to patients who were at least 18 years old
at diagnosis and for whom vital status at, and date of the last
follow-up were known. Patients ascertained for a second tumour
were excluded. Time-to-event was calculated from the date of
diagnosis. For prevalent cases with study entry after diagnosis, left
truncation was applied, i.e., follow-up started at the date of study
entry.27 Follow-up was right-censored at the date of death (death
known to be due to breast cancer considered an event), the date
the patient was last known to be alive if death did not occur or at
10 years after diagnosis, whichever came first. Follow-up was
censored at 10 years due to limited data availability after this time.
Hazard ratios (HR) for association of rs45446698 genotype with
breast cancer-specific survival were estimated using Cox propor-
tional hazards regression implemented in the R package survival
(v. 2.43–3) stratified by country. iCOGS and OncoArray estimates
were combined using an inverse-variance-weighted meta-analysis.
RESULTS
We tested 8,280,353 autosomal SNPs for association with luteal-
phase creatinine-adjusted oestrone-3-glucuronide and
pregnanediol-3-glucuronide in 560 premenopausal women. For
oestrone-3-glucuronide, we identified a single peak mapping to
the CYP3A locus at chromosome 7q22.1 (Fig. 1 and Supplementary
Table S3); conditioning on any of the top SNPs, there were no
additional independent signals. Four of the SNPs that were
significant at P < 1 × 10−8 comprise part of the seven-SNP
CYP3A7*1C allele,8,15 including the top, directly genotyped SNP,
rs45446698 (Supplementary Table S3). The rare rs45446698-C
allele (MAF= 0.035) was associated with a 49.2% reduction in
luteal-phase oestrone-3-glucuronide (95% CI −56.1% to −41.1%,
P= 3.1 × 10−18, Table 1) and explained 11.5% of the variation in
oestrone-3-glucuronide in these premenopausal women. Since
hormone levels may be influenced by both demographic and
reproductive factors, we adjusted for age at urine collection, age
at menarche, body mass index and parity; these adjustments did
not alter the association (fully adjusted model: 44.8% reduction,
95% CI −53.3% to −34.8%, P= 2.1 × 10−12, Table 1).
For pregnanediol-3-glucuronide, there were no associations
that were significant at a threshold of P < 1 × 10−8 (Supplementary
Fig. S2). An association between the CYP3A locus and progester-
one levels has been reported previously;10 accordingly, we
measured progesterone in addition to pregnanediol-3-
glucuronide in premenopausal women from the Generations
Study. Progesterone was moderately correlated with
pregnanediol-3-glucuronide (r= 0.37, P= 7.4 × 10−12), but while
there was no association between the rs45446698-C allele and
urinary pregnanediol-3-glucuronide levels (5.5% reduction, 95% CI
−24.2% to +17.7%, P= 0.61) in this group of women, the
rs45446698-C allele was associated with significantly lower luteal-
phase urinary progesterone levels (26.7% reduction, 95% CI
−39.4% to −11.6%, P= 0.001, Table 1). Adjusting these analyses
for covariates, as above, did not alter the results (Table 1).
To test for the association between rs45446698 and breast
cancer risk, we combined genotype data from 56 studies
(OncoArray; Supplementary Table S1) with imputed data from
35 studies (iCOGS; Supplementary Table S2) in a total of 90,916
cases and 89,893 controls of European Ancestry. The rs45446698-C
allele was associated with a reduction in breast cancer risk (OR=
0.94, 95% CI 0.91–0.98, P= 0.002, Table 2) with no evidence of
heterogeneity between data sets (Phet= 0.58). There was no
evidence that the reduction in breast cancer risk associated with
being a rs45446698-C carrier differed according to Her2 status,
tumour grade or stage (Supplementary Table S4). Stratifying by ER
status, the association was limited to ER-positive (ER+ ) breast
cancers (OR= 0.91, 95% CI 0.87–0.96, P= 0.0002 and OR= 1.03,
95% CI 0.95–1.11, P= 0.50 for ER+ and ER− cancers, respectively;
Pint= 0.03, Table 2). Stratifying by ER and PR status, the association
was limited to ER+ /PR+ cancers (ER+ /PR+ : OR= 0.86, 95% CI
0.82–0.91, P= 6.9 × 10–8; ER+ /PR−: OR= 1.06, 95% CI 0.96–1.16,
P= 0.25; Pint= 0.0001, Table 2). Adjusting for demographic and
reproductive factors in the subset of studies for which these
additional covariates were available did not alter this association
(Supplementary Table S5). Defining reference age as age at
diagnosis for cases and age at interview for controls and using this
as a proxy for menopausal status (<54 or ≥54 years), we further
stratified our analysis on menopausal status; there was little
evidence that the association with ER+ /PR+ breast cancer
differed by menopausal status (premenopausal OR= 0.94, 95%
CI 0.84–1.06, P= 0.31, postmenopausal OR= 0.86, 95% CI
0.80–0.93, P= 0.0001, Phet= 0.28).
On the assumption that genetic variants that influence
metabolism of endogenous hormones5 may also impact on
metabolism of exogenous hormones, we investigated whether
menopausal hormone treatment modified the association
between rs45446698 genotype and ER+ /PR+ breast cancer risk
in 17,831 postmenopausal breast cancer cases and 40,437
postmenopausal controls. The rs45446698-C carrier OR was lower
(i.e., more protective) in current users of any menopausal hormone
treatment but particularly in those who used combined
oestrogen–progesterone therapy (current users: OR= 0.68, 95%
CI 0.52–0.90, P= 0.007; never users: OR= 0.85, 95% CI 0.76–0.95,
P = 0.005, Table 3). This difference was not, however, statistically
significant (Pint= 0.15, Table 3).
Finally, to determine whether rs45446698 genotype could affect
patient outcome by influencing metabolism of cytotoxic agents
that are CYP3A substrates,15 we tested for the association
between rs45446698 genotype and 10-year breast cancer-
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Fig. 1 Manhattan plot of single-nucleotide polymorphism (SNP) associations with luteal-phase urinary oestrone-3-glucuronide levels in
560 premenopausal women. –log10 P values for SNP associations are plotted against the genomic coordinates (hg19). The red line indicates
the conventionally accepted threshold for genome-wide significance (P= 1 × 10−8).
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for whom follow-up data were available. There was neither overall
association between rs45446698 genotype and breast cancer-
specific survival (HR= 0.99, 95% CI 0.91–1.09, P= 0.90, Table 4)
nor was there any evidence of an association in analyses stratified
by tumour characteristics (Supplementary Table S6). Stratifying by
treatment regimen, we found no evidence that rs45446698
genotype influenced outcome in cases who were treated with a
hormonal agent (i.e., tamoxifen or an aromatase inhibitor, Table 4).
There was, however, some evidence that in cases who were
treated with a taxane, carriers of the rs45446698-C allele had
reduced breast cancer-specific survival compared with non-
carriers (HR= 1.46, 95% CI 1.08–1.97, P= 0.01, Table 4).
DISCUSSION
This present GWAS identified a single, highly significant associa-
tion between the CYP3A7*1C allele (tagged by rs4546698) and
premenopausal urinary oestrone-3-glucuronide. This finding alone
is not novel; we have previously reported an association between
the CYP3A7*1C allele, parent oestrogens and several oestrogen
metabolites.5 What we have demonstrated for the first time is the
extent to which this signal dominates the genetic architecture of
hormone levels in premenopausal women of Northern European
ancestry (Fig. 1; rs45446698 P= 3.1 × 10−18, all other signals P >
1 × 10–8) and we estimate that 11.5% of the variance in urinary
oestrone-3-glucuronide levels is explained by this one allele.
Two previous GWAS of circulating oestrogen levels have been
published, neither reported an association with the CYP3A
locus.9,10 This lack of replication may be explained by our choice
of study population. The first GWAS9 was conducted in
postmenopausal women (N= 1623) participating in the Nurses’
Health Study and the Sisters in Breast Screening Study. The
second was conducted within the Twins UK study (N= 2913) and
included men as well as pre-, peri- and postmenopausal women. A
strength of our GWAS is that all of the women were premeno-
pausal and had regular menstrual cycles; circulating levels of
oestrogens in premenopausal women are much higher compared
with those in postmenopausal women.4,28 For each woman, we
assayed a single urine sample taken in the mid-luteal phase of her
cycle at exactly 7 days after her predicted day of ovulation. Thus,
although our study is relatively small (N= 560), we may have had
greater power to detect an association at the CYP3A locus than
previous studies due to the very homogeneous premenopausal
study population that we selected.
Table 1. Association of rs45446698 with levels of oestrone-3-glucuronide, pregnanediol-3-glucuronide and progesterone in premenopausal women
of European ancestry.
Hormone Geometric mean by
rs45446698 genotype
(µmol/mol)
Unadjusted analysis Adjusted analysisa
AA AC/CC % change P % change P
GWAS (N= 560)
Oestrone-3-glucuronide 9.74 4.95 −49.2 (−56.1 to −41.1) 3.1 × 10–18 −44.8 (−53.3 to −34.8) 2.1 × 10–12
Pregnanediol-3-glucuronide 0.78 0.70 −10.1 (−22.5 to 4.3) 0.16 −9.3 (−22.9 to 6.8) 0.24
Follow-up progesterone analysis (N= 298)
Oestrone-3-glucuronide 9.77 4.39 −55.0 (−63.1 to −45.1) 2.6 × 10–15 −55.1 (−63.6 to −44.7) 4.0 × 10–14
Pregnanediol-3-glucuronide 0.79 0.75 −5.5 (−24.2 to 17.7) 0.61 −9.6 (−27.9 to 13.3) 0.38
Progesterone 29.37 21.51 −26.7 (−39.4 to −11.6) 0.001 −24.3 (−37.6 to −8.2) 0.005
aAnalysis was adjusted for age at menarche (<12, 12, 13, 14 and >14 years), age at collection of urine samples (<35, 35–40 and ≥40 years), body mass index
(<18.5, 18.5–<20.0, 20.0–<25.0, 25.0–<30.0 and ≥30.0 kg/m2) and parity (0, 1, 2 and ≥3 live births).
Table 2. Association of rs45446698 among women of European ancestry overall and stratified by hormone receptor status.
iCOGS OncoArray Combined
Cases Controls OR (95% CI) P1 Cases Controls OR (95% CI) P1 Cases Controls OR (95% CI) P1
All subjects 36,859 37,320 0.93 (0.87–0.98) 0.01 54,057 52,573 0.95 (0.91–1.00) 0.05 90,916 89,893 0.94 (0.91–0.98) 0.002
Phet= 0.58
ER+ 19,950 28,820 0.90 (0.84–0.97) 0.007 28,478 40,223 0.92 (0.87–0.98) 0.01 48,428 69,043 0.91 (0.87–0.96) 0.0002
ER− 4298 28,820 1.04 (0.92–1.18) 0.56 6592 40,223 1.03 (0.92–1.14) 0.64 10,890 69,043 1.03 (0.95–1.11) 0.50
NK 5087 8380
Total 29,335 28,820 Pint= 0.06 4450 40,223 Pint= 0.19 Pint= 0.03
PR+ 13,995 28,820 0.85 (0.78–0.93) 0.0002 21,500 40,223 0.87 (0.81–0.93) 0.0001 35,495 69,043 0.86 (0.82–0.91) 5.8 × 10–8
PR− 6154 28,820 1.06 (0.95–1.18) 0.33 10,058 40,223 1.05 (0.96–1.15) 0.26 16,212 69,043 1.05 (0.98–1.12) 0.18
NK 9186 11,892
Total 29,335 28,820 Pint= 0.001 43,450 40,223 Pint= 0.0004 Pint= 1.3 × 10
–6
ER+ , PR+ 13,508 28,820 0.85 (0.78–0.93) 0.0003 20,624 40,223 0.87 (0.81–0.93) 0.0001 34,132 69,043 0.86 (0.82–0.91) 6.9 × 10–8
ER+ , PR− 2890 28,820 1.03 (0.89–1.20) 0.66 4597 40,223 1.07 (0.96–1.21) 0.21 7487 69,043 1.06 (0.96–1.16) 0.25
NK 12,937 18,229
Total 29,335 28,820 Pint= 0.02 43,450 40,223 Pint= 0.001 Pint= 0.0001
P1 test of H0 no association between rs45446698 and breast cancer risk, Pint test of H0 no difference between stratum-specific estimates, Phet test of H0 no
difference between iCOGS and OnocoArray data, NK not known.
Studies with less than 50 cases in any stratum were excluded from the stratified analyses leaving 16 studies for analysis in iCOGS data and 32 studies for
analysis in OncoArray data.
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Our findings also demonstrate the potential significance of the
choice of hormone or hormone metabolite; both of the previous
GWAS assayed plasma oestradiol. In a targeted analysis of urinary
oestrogen metabolites, we have previously shown that the
association between the CYP3A7*1C allele and oestrone (45.3%
lower levels in carriers, P= 0.0005) is more pronounced than the
association with oestradiol (26.7% lower levels, P= 0.07) with the
implication that measuring urinary oestrone-3-glucuronide (rather
than plasma oestradiol) may have contributed to our positive
findings. Similarly, by measuring pregnanediol-3-glucuronide and
progesterone in premenopausal women from the Generations
Study, we were able to demonstrate a significant association of
rs45446698 with progesterone (27% reduction, P= 0.001) in the
absence of an association with pregnanediol-3-glucuronide (6%
reduction, P= 0.61).
The fact that we measured a urinary oestrogen metabolite
(oestrone-3-glucuronide) rather than serum or plasma oestrogens
(oestradiol or oestrone) limits the interpretation of our results in
terms of a causal association. Estimates of the association between
circulating oestrogens and breast cancer risk are based on
measurements of hormone levels in plasma or serum,3 and in a
recent study that measured luteal-phase serum oestrogens and
urinary oestrogen metabolites in 249 premenopausal women,29
serum oestradiol and oestrone were only moderately correlated
with urinary oestrone (serum oestradiol: r= 0.39, serum oestrone:
r= 0.48). Our analysis of rs45446698 genotypes in 90,916 cases
and 89,893 controls from BCAC, however, provides robust
evidence of an association of the CYP3A7*1C allele with
breast cancer risk overall (OR= 0.94, P= 0.002) and a more
pronounced protective effect on ER+ /PR+ breast cancers (OR=
0.86, P= 6.9 × 10−8). The specificity of this association (comparing
ER+ /PR− with ER+ /PR+ cancers, Phet= 0.001) and our replica-
tion of Ruth and colleagues report of a signal at the CYP3A locus in
their analysis of circulating progesterone levels10 raise the
possibility that premenopausal progesterone levels might influ-
ence risk of ER+ /PR+ breast cancers. This would be in contrast to
the findings from Key et al. who reported no evidence of
an association between premenopausal progesterone levels and
Table 3. Association of rs45446698 genotype with ER+ /PR+ breast cancer risk among women of European ancestry stratified by current use of
postmenopausal hormone treatment.
iCOGS OncoArray Combined
Cases Controls OR (95% CI) P1 Cases Controls OR (95% CI) P1 Cases Controls OR (95% CI) P1
MHT− 3742 8902 0.73 (0.62–0.86) 0.0002 5961 15,128 0.95 (0.83–1.08) 0.45 9703 24,030 0.86 (0.78–0.95) 0.003
MHT+ 1593 2859 0.77 (0.59–0.99) 0.04 2823 5529 0.87 (0.71–1.06) 0.16 4416 8388 0.83 (0.70–0.97) 0.02
NK 622 1793 3090 6226 3712 8019
Total 5957 13,554 Pint= 0.81 11,874 26,883 Pint= 0.26 17,831 40,437 Pint= 0.47
EPT− 3736 7826 0.77 (0.65–0.91) 0.002 4173 8566 0.93 (0.80–1.09) 0.38 7909 16,392 0.85 (0.76–0.95) 0.005
EPT+ 727 944 0.71 (0.48–1.05) 0.09 878 1170 0.66 (0.45–0.97) 0.03 1605 2114 0.68 (0.52–0.90) 0.007
NK 1494 4784 6823 17,147 8317 21,931
Total 5957 13,554 Pint= 0.72 11,874 26,883 Pint= 0.09 17,831 40,437 Pint= 0.15
ET− 3840 7710 0.75 (0.63–0.88) 0.0005 4343 8136 0.92 (0.79–1.07) 0.29 8183 15,846 0.88 (0.79–0.97) 0.01
ET+ 589 1172 0.69 (0.45–1.06) 0.09 640 1484 0.94 (0.62–1.42) 0.76 1229 2656 0.84 (0.64–1.10) 0.21
NK 1528 4672 6891 17,263 8419 21,935
Total 5957 13,554 Pint= 0.83 11,874 26,883 Pint= 0.85 17,831 40,437 Pint= 0.78
MHT menopausal hormone treatment, EPT oestrogen–progesterone therapy, ET oestrogen-only therapy, P1 test of H0 no association between rs45446698
and ER+ /PR+ breast cancer risk, Pint test of H0 no difference between stratum-specific estimates, NK not known.
Studies with less than 50 cases in any stratum were excluded from the stratified analyses leaving 13 studies for analysis in iCOGS data and 27 studies for
analysis in OncoArray data. All models are adjusted for reference age, study, ten principal components and former use of MHT. Additionally, when stratified by
EPT or ET, models are adjusted for use of any other type of MHT other than the one of interest. Further adjusting for age at menarche (<12, 12, 13, 14, >14),
parity (0, 1, 2 and ≥3 live births) and BMI ( < 18.5, 18.5–<20.0, 20.0–<25.0, 25.0–<30.0 and ≥30.0 kg/m2) did not alter these results.
Table 4. Association of rs45446698 with breast cancer-specific survival in breast cancer cases of European Ancestry stratified by treatment regimen.
Group iCOGS OncoArray Combined
Cases Events HR (95% CI) P1 Cases Events HR (95% CI) P1 HR (95% CI) P1 Phet
All breast cancer patients 32,743 2580 0.93 (0.80–1.08) 0.35 58,796 3799 1.04 (0.92–1.17) 0.57 0.99 (0.91–1.09) 0.90 0.28
Only patients that
Received tamoxifen 9766 825 1.22 (0.95–1.57) 0.13 7803 746 0.95 (0.73–1.23) 0.68 1.08 (0.90–1.30) 0.41 0.18
Received aromatase inhibitor 3794 246 0.94 (0.58–1.54) 0.82 5460 247 1.03 (0.64–1.65) 0.91 0.99 (0.70–1.39) 0.94 0.81
Received CMF-like CT 919 99 0.30 (0.09–1.01) 0.05 1692 229 0.88 (0.55–1.41) 0.60 0.77 (0.50–1.19) 0.24 0.11
Received taxanes* 1806 160 1.69 (0.96–2.99) 0.07 3836 299 1.37 (0.96–1.96) 0.08 1.46 (1.08–1.97) 0.01 0.54
Received anthracycline therapy 4625 418 1.21 (0.83–1.75) 0.32 6740 771 1.07 (0.82–1.38) 0.63 1.11 (0.90–1.37) 0.33 0.58
CMF cyclophosphamide methotrexate fluorouracil, CT chemotherapy, P1 test of H0 no association between rs45446698 and breast cancer-specific survival,
Phet test of H0 no difference across genotyping platforms.
In total, 38 studies from iCOGS and 63 studies from OnocoArray provided follow-up data for analysis of breast cancer-specific survival. The results were
censored at 10 years after diagnosis. HR for association of rs45446698 genotype with breast cancer-specific survival was estimated using Cox proportional
hazards regression stratified by country.
*To test for statistical interaction between rs45446698 genotype and treatment with a taxane, we additionally compared the association in cases who received
chemotherapy including a taxane to that in cases who received chemotherapy that did not include a taxane (Pint= 0.02; the association in the latter group was
in the opposite direction and not significant: HR= 0.88, 95% CI 0.67–1.15, P= 0.34).
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breast cancer risk overall and no heterogeneity in estimates
stratified by PR status.3 However, the number of cases of PR+
(N= 158) and PR− (N= 61) breast cancer was small, and this
analysis may have lacked power to detect modest associations in
subgroups of cancers. Alternatively, the association of rs45446698
genotype with ER+ /PR+ breast cancer risk, specifically, may be
due to the fact that PR is a marker for an intact oestrogen
signalling pathway30 confirming a direct link between the levels of
oestrogen (or oestrogen signalling) and proliferation in this
subgroup of cancers.
Our analysis of the CYP3A7*1C allele, menopausal hormone
treatment and breast cancer risk was inconclusive; while the
carrier ORs were consistent with a greater protective effect of this
allele in women taking exogenous hormones, particularly
oestrogen–progesterone therapy, none of the interactions was
statistically significant. Overall, there were 14,119 ER+ /PR+
breast cancer cases and 32,418 controls for this subgroup analysis,
but for what was, arguably, the most pertinent subgroup (i.e.,
current oestrogen–progesterone therapy use), the number of
cases who were current users was relatively small (CYP3A7*1C
carriers N= 107, non-carriers N= 1498) and power was limited to
detect modest interactions. There are limitations to this analysis;
we focussed on current menopausal hormone treatment use
(adjusted for past use) as it is for current use that the association
with breast cancer risk is the strongest,31 but we did not have
information on dose, duration or the formulation that was used.
Finally, we found no association between CYP3A7*1C carrier
status and survival in patients treated with tamoxifen, a known
CYP3A substrate. This may reflect the fact that compared to
CYP3A4, CYP3A7 is a poor metaboliser of tamoxifen,32 or that
standard doses of tamoxifen achieve high levels of oestrogen
receptor saturation.33 There was some evidence that breast
cancer-specific survival was reduced in CYP3A7*1C carriers who
were treated with a taxane, compared with non-carriers (P= 0.01);
this may, however, be a chance finding given the number of
comparisons that were tested.
In conclusion, we present strong evidence that the CYP3A7*1C
allele impacts on the metabolism of endogenous hormones,
which in turn, reduces the risk of hormone receptor-positive
breast cancer in carriers. Optimal strategies for breast cancer
prevention in women at high risk of breast cancer and in the
general population are an area of active research. In this context,
CYP3A7*1C carriers represent a naturally occurring cohort in which
the effects of reduced exposure to endogenous oestrogens and
progesterones throughout a woman’s premenopausal years can
be further investigated. Our results regarding the impact of
CYP3A7*1C carrier status on exogenous hormones and chemother-
apeutic agents are preliminary but warrant further investigation,
preferably in the setting of randomised trials.
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